Biofilm formation by fluconazole-resistant Candida albicans strains is inhibited by fluconazole

Journal of Antimicrobial Chemotherapy

Volumn 59, Issue 3, 2007, Pages 441-450

  Bruzual, Igor ^a   Riggle, Perry ^a   Hadley, Susan ^b   Kumamoto, Carol A ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TUFTS MEDICAL CENTER   (United States)

Author keywords

C. albicans; Drug resistance; MDR1

Indexed keywords

FLUCONAZOLE; ANTIFUNGAL AGENT; FUNGAL PROTEIN; HWP1 PROTEIN, CANDIDA ALBICANS; MEMBRANE PROTEIN; UNCLASSIFIED DRUG;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BIOFILM; CANDIDA ALBICANS; CELL ADHESION; CONTROLLED STUDY; CULTURE MEDIUM; DRUG EFFICACY; FUNGAL CELL; FUNGAL STRAIN; GROWTH INHIBITION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; DRUG EFFECT; GENETICS; GROWTH, DEVELOPMENT AND AGING;

ANTIFUNGAL AGENTS; BIOFILMS; CANDIDA ALBICANS; DRUG RESISTANCE, FUNGAL; FLUCONAZOLE; FUNGAL PROTEINS; MEMBRANE GLYCOPROTEINS;

EID: 34248233604     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkl521     Document Type: Article

References (45)

1. Morschhauser J. The genetic basis of fluconazole resistance development in Candida albicans. Biochim Biophys Acta 2002; 1587: 240-8.
2. Ramage G, Saville SP, Thomas DP et al. Candida biofilms: An update. Eukaryot Cell 2005; 4: 633-8.
3. Nobile CJ, Mitchell AP. Regulation of cell-surface genes and biofilm formation by the C. albicans transcription factor Bcr1p. Curr Biol 2005; 15: 1150-5.
4. Wu T, Wright K, Hurst SF et al. Enhanced extracellular production of aspartyl proteinase, a virulence factor, by Candida albicans isolates following growth in subinhibitory concentrations of fluconazole. Antimicrob Agents Chemother 2000; 44: 1200-8.
5. Donlan RM, Costerton JW. Biofilms: Survival mechanisms of clinically relevant microorganisms. Clin Microbiol Rev 2002; 15: 167-93.
6. Douglas LJ. Medical importance of biofilms in Candida infections. Rev Iberoam Micol 2002; 19: 139-43.
7. Kojic EM, Darouiche RO. Candida infections of medical devices. Clin Microbiol Rev 2004; 17: 255-67.
8. Kumamoto CA. Candida biofilms. Curr Opin Microbiol 2002; 5: 608-11.
9. Lopez-Ribot JL. Candida albicans biofilms: More than filamentation. Curr Biol 2005; 15: R453-5.
10. Baillie GS, Douglas LJ. Effect of growth rate on resistance of Candida albicans biofilms to antifungal agents. Antimicrob Agents Chemother 1998; 42: 1900-5.
11. Baillie GS, Douglas LJ. Matrix polymers of Candida biofilms and their possible role in biofilm resistance to antifungal agents. J Antimicrob Chemother 2000; 46: 397-403.
12. Bachmann SP, VandeWalle K, Ramage G et al. In vitro activity of caspofungin against Candida albicans biofilms. Antimicrob Agents Chemother 2002; 46: 3591-6.
13. Kumamoto CA, Vinces MD. Alternative Candida albicans life-styles: growth on surfaces. Annu Rev Microbiol 2005; 59: 113-3.
14. Mukherjee PK, Chandra J, Kuhn DM et al. Mechanism of fluconazole resistance in Candida albicans biofilms: Phase-specific role of efflux pumps and membrane sterols. Infect Immun 2003; 71: 4333-40.
15. Ramage G, Bachmann S, Patterson TF et al. Investigation of multidrug efflux pumps in relation to fluconazole resistance in Candida albicans biofilms. J Antimicrob Chemother 2002; 49 973-80.
16. Mukherjee PK, Chandra J. Candida biofilm resistance. Drug Resist Updat 2004; 7: 301-9.
17. Kuhn DM, George T, Chandra J et al. Antifungal susceptibility of Candida biofilms: Unique efficacy of amphotericin B lipid formulations and echinocandins. Antimicrob Agents Chemother 2002; 46: 1773-80.
18. Kuhn DM, Ghannoum MA. Candida biofilms: Antifungal resistance and emerging therapeutic options. Curr Opin Investig Drugs 2004; 5 186-97.
19. Fonzi WA, Irwin MY. Isogenic strain construction and gene mapping in Candida albicans. Genetics 1993; 134: 717-28.
20. Riggle PJ, Kumamoto CA. Role of a Candida albicans P1-type ATPase in resistance to copper and silver ion toxicity. J Bacteriol 2000; 182: 4899-905.
21. Gillum AM, Tsay EY, Kirsch DR. Isolation of the Candida albicans gene for orotidine-5′-phosphate decarboxylase by complementation of S. oerevisiae ura3 and E. coli pyrF mutations. Mol Gen Genet 1984; 198: 179-82.
22. National Committee for Clinical Laboratory Standards. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically - Second Edition: Approved Standard M7-A2. NCCLS, Villanova, PA, USA, 1990.
23. Provine H, Hadley S. Preliminary evaluation of a semisolid agar antifungal susceptibility test for yeasts and molds. J Clin Microbiol 2000; 38: 537-41.
24. Ausubel FM. Short Protocols in Molecular Biology: A Compendium of Methods From Current Protocols in Molecular Biology. 5th edn. Hoboken, NJ: Wiley, 2002.
25. Brown DH Jr, Giusani AD, Chen X et al. Filamentous growth of Candida albicans in response to physical environmental cues and its regulation by the unique CZF1 gene. Mol Microbiol 1999; 34: 651-62.
26. Kumamoto CA. A oontact-activated kinase signals Candida albicans invasive growth and biofilm development. Proc Natl Acad Sci USA 2005; 102: 5576-81.
27. Ramage G, Vandewalle K, Wickes BL et al. Characteristics of biofilm formation by Candida albicans. Rev Iberoam Micol 2001; 18: 163-70.
28. Sambrook J, Fritsch EF, Maniatis T. Molecular Cloning: A Laboratory Manual. 2nd edn. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory, 1989.
29. Ramage G, Vande Walle K, Wickes BL et al. Standardized method for in vitro antifungal susceptibility testing of Candida albicans biofilms. Antimicrob Agents Chemother 2001; 45: 2475-9.
30. Chandra J, Kuhn DM, Mukherjee PK et al. Biofilm formation by the fungal pathogen Candida albicans: Development, architecture, and drug resistance. J Bacteriol 2001; 183: 5385-94.
31. Marchetti O, Majcherczyk PA, Glauser MP et al. Sensitive bioassay for determination of fluconazole concentrations in plasma using a Candida albicans mutant hypersusceptible to azoles. Antimicrob Agents Chemother 2001; 45: 696-700.
32. Louie A, Liu QF, Drusano GL et al. Pharmacokinetic studies of fluconazole in rabbits characterizing doses which achieve peak levels in serum and area under the concentration-time curve values which mimic those of high-dose fluconazole in humans. Antimicrob Agents Chemother 1998; 42: 1512-4.
33. Ramage G, Saville SP, Wickes BL et al. Inhibition of Candida albicans biofilm formation by famesol, a quorum-sensing molecule. Appl Environ Microbiol 2002; 68: 5459-63.
34. Homby JM, Nickerson KW. Enhanced production of famesol by Candida albicans treated with four azoles. Antimicrob Agents Chemother 2004; 48: 2305-7.
35. Kruppa M, Krom BP, Chauhan N et al. The two-component signal transduction protein Chk1p regulates quorum sensing in Candida albicans. Eukaryot Cell 2004; 3: 1062-5.
36. Cocuaud C, Rodier MH, Daniault G et al. Anti-metabolic activity of caspofungin against Candida albicans and Candida parapsilosis biofilms. J Antimicrob Chemother 2005; 56: 507-12.
37. Staab JF, Bradway SD, Fidel PL et al. Adhesive and mammalian transglutaminase substrate properties of Candida albicans Hwp1. Science 1999; 283: 1535-8.
38. Hogan DA, Vik A, Kolter RA. Pseudomonas aeruginosa quorum-sensing molecule influences Candida albicans morphology. Mol Microbiol 2004; 54: 1212-23.
39. Nobile CJ, Mitchell AP. Genetics and genomics of Candida albicans biofilm formation. Cell Microbiol 2006; 8: 1382-91.
40. Suci PA, Tyler BJ. Action of chlorhexidine digluconate against yeast and filamentous forms in an early-stage Candida albicans biofilm. Antimicrob Agents Chemother 2002; 46: 3522-31.
41. Garcia-Sanchez S, Aubert S, Iraqui I et al. Candida albicans biofilms: A developmental state associated with specific and stable gene expression patterns. Eukaryot Cell 2004; 3: 536-45.
42. d'Enfert C. Biofilms and their role in the resistance of pathogenic Candida to antifungal agents. Curr Drug Targets 2006; 7: 465-70.
43. Shin JH, Kee SJ, Shin MG et al. Biofilm production by isolates of Candida species recovered from nonneutropenic patients: Comparison of bloodstream isolates with isolates from other sources. J Clin Microbiol 2002; 40: 1244-8.
44. Calera JA, Calderone R. Flocculation of hyphae is associated with a deletion in the putative CaHK1 two-component histidine kinase gene from Candida albicans. Microbiology 1999; 145: 1431-42.
45. Riggle PJ, Kumamoto CA. Transcriptional regulation of MDR1, encoding a drug efflux determinant, in fluconazole-resistant Candida albicans strains through an Mcm1p binding site. Eukaryot Cell 2006; 5: 1957-68.